|
Assessment of Tumor Response to Treatment Using Level Set Clustering in PET Images
Application
Tumor response algorithm that corrects for anatomical changes and robustly identifies local changes in serial PET images through a clustering algorithm.
Key Benefits
Robust to noise and outliers and can tolerate imperfections in data acquisition.
Could be applicable to many other imaging modalities in radiation therapy.
More accurately...
Published: 2/13/2025
Contributor(s): Timothy Fox, Eduard Schreibmann
|
|
Enhanced Delivery and Efficacy of Antisense Drugs via Covalently Linked Nanodisc Scaffolds
Application
A synthetic nanodisc (ND) scaffold for delivering antisense oligonucleotides (ASOs) for the treatment of disease.
Key Benefits
Improved cellular uptake and protein suppression using antisense oligos.
Longer ASO half-life compared to other ASO delivery methods.
Potential to overcome the delivery and efficacy challenges using ASOs for...
Published: 2/13/2025
Contributor(s): Khalid Salaita, Radhika Sharma
|
|
Repurposing a Potent MDM2 Inhibitor for Leukemia Treatment
Application
VERU-111, also known as sabizabulin, is a potent microtubule inhibitor and, notably, an MDM2 inhibitor. This repurposed compound demonstrates remarkable efficacy in the treatment of Acute Myeloid Leukemia (AML).
Key Benefits
Unique dual-action functionality as a microtubule and MDM2 inhibitor.
Successful inhibition of MDM2, an oncogene...
Published: 2/13/2025
Contributor(s): Deborah DeRyckere, Muxiang Zhou, Lu Bing Gu, Douglas Graham, Tao Liu
|
|
Optimizing the Engineering of CAR-T Cells
Application
A method for selecting distinct T cell populations in order to generate more effective CAR-T cells.
Key Benefits
The proposed invention focuses on selecting the optimal “starting material” for the engineering CAR-T cells.
This selection method can be utilized for the development of any and all CAR-T therapies, not limited...
Published: 2/13/2025
Contributor(s): Byron Au-Yeung
|
|
Indolium 1 for Advanced Melanoma Treatment
Application
A small molecule compound for the treatment of melanoma.
Key Benefits
Novel small molecule compound for the treatment of resistant melanoma.
Well tolerated in vivo.
Market Summary
Malignant melanoma is a type of skin cancer that begins in melanocyte cells. Melanoma is the 19th most commonly occurring cancer. Exposure to UV radiation...
Published: 2/13/2025
Contributor(s): Jack Arbiser
|
|
Drug Platform for L-Asparaginases for the Treatment of Leukemias
Application
A novel humanized therapeutic L-asparaginase compound to treat acute lymphoblastic leukemia (ALL) and other cancers.
Key Benefits
A novel drug discovery platform for developing asparaginase-based compounds to treat leukemias and other cancers.
The derivatives could exhibit less immunogenicity and systemic toxicity than FDA-approved...
Published: 2/13/2025
Contributor(s): Sunil Raikar, Christopher Doering, H. (Harold) Trent Spencer, Kristopher Knight, Harrison Brown
|
|
Markers Predictive of Therapeutic Response in B-cell Malignancies
Application
Test to detect NF-kB2 breaks to guide treatment with proteasome inhibitors and its use with other therapeutic agents.
Key Benefits
Improved the prediction model to determine which patients are more likely to respond to bortezomib treatment.
Improved the efficacy of treatment for patients with multiple myeloma and lymphomas.
Market...
Published: 2/13/2025
Contributor(s): Leon Bernal-Mizrachi
|
|
Vaccines and Antibody Therapeutics for HPV-related Cancers
Application
Treatment and prevention of HPV-induced malignancies.
Key Benefits
Identification of a protein expressed in a large number of HPV-induced cancers.
Antibodies have been generated that bind to the protein and potentially elicit an immune response to the cancer cells.
The antibodies can be used to develop new treatments and vaccines...
Published: 2/13/2025
Contributor(s): Rafi Ahmed, Andreas Wieland
|
|
Non-invasive Probes to Determine Efficacy of Cancer Therapies
Application
A real-time, non-invasive probe to determine the efficacy of cancer immunotherapies.
Key Benefits
Determines immunotherapy success in patients.
CAR cells can be tested before putting it back in the patients.
Simple diagnostic with readout in 30 minutes compared to 2-3 days.
Market Summary
Lymphoblastic leukemia is one of the most...
Published: 2/13/2025
Contributor(s): Anna Kellner, Khalid Salaita, Curtis Henry
|
|
Vaccine-pulsed Dendritic Cells as a Treatment for Aggressive Breast Cancers
Application
Immunotherapy for HER2+ and triple-negative breast cancer.
Key Benefits
Autologous vaccine comprising patient-specific tumor antigens and immune stimulatory components against aggressive breast cancers.
Prepared outside of the body and then administered to patients.
Preclinical data indicate treatment decreases tumor growth and improves...
Published: 2/13/2025
Contributor(s): Periasamy (Selva) Selvaraj, Luis Munoz, Ramireddy Bommireddy, Christopher Pack, Shaker Reddy, Sampath Ramachandiran
|
